CDK4/6 inhibitors, like Palbociclib, exert their anti-tumor effects by maintaining the retinoblastoma gene (Rb) in a non-phosphorylated state, leading to cell cycle arrest, cell senescence, apoptosis, and enhanced immunogenicity (17, 32, 33). This evidence concerns the gene RB1 and neoplasm.